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Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic enzymatic disorder af-fects millions of people worldwide.1,2 About 
7.5% of the population of the world are carriers for 
G6PD deficiency, ranging from 0.1% in Japan and some 
European areas to 35% in Africa, Southern Europe, the 
Middle East, and Southeast Asia.3-5 The condition is 
usually asymptomatic, but ingestion of or contact with 
fava beans, drugs or chemicals, or bacterial or viral in-
fections may cause acute hemolytic anemia.6,7 As G6PD 
deficiency is an X-linked genetic abnormality the clini-
cal manifestations of G6PD deficiency are much more 
common in male homozygotes than in females heterozy-
gotes. This genetic abnormality is associated with a range 
of clinical conditions. Some subjects are asymptomatic, 
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BACKGROUND AND OBJECTIVES: Glucose-6-phosphate dehydrogenase (G6pd) deficiency is a genetic enzy-
matic disorder that affects millions of people worldwide, and is a major health problem in Jordan. We studied 
factors that may predict severe hemolysis in children with G6pd deficiency.
METHODS: We reviewed the records of patients with low G6pd activity admitted to a teaching hospital be-
tween 1996 to 2007. We collected demographic data, details of sign and symptoms, history and type of fava 
bean ingestion, blood and rh group, history of neonatal jaundice, history and type of drug use, abdominal pain 
at admission and the results of tests for hemoglobin, white blood cells (Wbc), and hepatic function. We classi-
fied patients into mild and severe groups based on hemoglobin levels at admission.
RESULTS: of 428 children with G6pd deficiency, 79 (18%) were severe cases and 349 (82%) patients with mild 
disease. there were no statistically significant differences in most factors between the two groups. factors that 
achieved statistical significance for severe hemolysis included younger age (P<.05), male gender (P<.05), higher 
alkaline phosphatase (alp) (P<.05), presence of fever at admission (P<.01), presence of vomiting during the at-
tack (P=.006), and a negative family history for G6pd deficiency (P=.005).
CONCLUSIONS: severe hemolysis can be predicted during hemolytic episodes in children with low G6pd by 
young age, male gender, a negative family history of G6pd deficiency, the presence of fever and vomiting and 
a high alp.
whereas others suffer from neonatal jaundice, acute he-
molytic anemia or rarely severe non-spherocytic hemo-
lytic anemia.8,9 Patients with hemolysis are always G6PD 
deficient, but not all G6PD deficient individuals develop 
hemolysis following exposure to oxidant stresses, pre-
sumably because other factors are involved.7,10,11 G6PD 
deficiency is still a major health problem in Jordan. This 
study was conducted to assess for the presence of any 
factors in the medical history or results of investigations 
that might be associated with severe hemolysis in chil-
dren with G6PD deficiency treated at Princess Rahma 
Hospital over an 11-year period.
METHODS
We reviewed the medical charts of patients with G6PD 
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deficiencies who presented with acute intravascular 
hemolysis and who were admitted to Princess Rahma 
Children’s Hospital in Irbid, Jordan between January 
1996 and December 2007. We included all patients with 
a clinical diagnosis of acute hemolysis and a confirmed 
diagnosis of G6PD deficiency by measuring the level 
G6PD enzyme activity at admission. Some individuals 
with severe hemolysis may have had normal red cells at 
the time of hemolysis, only to revert to a deficiency state a 
few weeks later. Patients with suspected G6PD deficien-
cy, but with a normal test, were invited for a repeat test 6 
weeks later to confirm the diagnosis. If they did not have 
G6PD deficiency, they were excluded from the study. 
The criteria for clinical diagnosis was when the child 
presented with sudden pallor, jaundice and had a dark 
or cola-colored urine, an elevated reticulocyte count, in-
direct bilirubin, and lactate dehydrogenase. Ethical com-
mittee approval was obtained from the Princess Rahma 
Children’s Hospital Research Committee.
 To assess the predictors of severity, we divided the 
patients into mild and severe groups based only on 
their hemoglobin at the time of admission. If it was less 
than ≤5 g/L, it was regarded as severe hemolysis and 
if more it was regarded as mild hemolysis. A special 
data collection sheet was developed for the sake of the 
study. Differences in clinical and biological characteris-
tics between the two groups were collected for the two 
study groups and analyzed using the Fisher exact test, 
the chi-square test, and the t test wherever appropriate. 
Information about potential predictors of hemolysis 
were collected including patient age at admission, gen-
der, white blood cell count (WBC) at admission, ala-
nine aminotransferase (ALT) level at admission, aspar-
tate aminotransferase (AST) level at admission, pres-
ence of fever (defined as temperature ≥38°C orally) at 
admission, fava bean ingestion or exposure (fresh vs. 
cooked vs. dried), presence of vomiting during the at-
tack, presence of a positive family history with G6PD 
deficiency (defined as history of hemolysis in the fam-
ily secondary to G6PD deficiency), blood group (O vs. 
A. vs B vs. AB), Rh positive vs. negative, history of neo-
natal jaundice, drug use (defined as any drug that in-
duced hemolysis in G6PD deficiency), prior infection 
(defined by clinical presentation or confirmation by 
laboratory investigation), and presence of abdominal 
pain at admission. A P value of less than .05 was con-
sidered statistically significant. The Statistical Package 
for Social Sciences (SPSS, version 15) software was 
used to analyze data.
RESULTS
Of 428 children with G6PD deficiency, 79 (18%) were 
severe cases and 349 (82%) patients with mild disease 
(Table 1). Severe cases were significantly younger than 
mild cases. Pallor of abrupt onset and passage of cola-
colored urine were universal presenting symptoms for 
all the cases. Incriminating factors responsible for he-
molysis included ingestion of fava beans (n=399), drug 
intake (n=30) and infection (n=75), with more than 
one predisposing condition existing in some children. 
A marked elevation in serum bilirubin, coinciding with 
intravascular hemolysis, was a feature in all the 428 
children with G6PD deficiency.
There was no statistically significant difference in 
the mean white blood cells count (WBC) at admission, 
ALT level at admission, AST level at admission, type of 
fava bean ingestion, blood group, Rh positivity, history 
of neonatal jaundice, drug use (defined as any drug that 
is known to induce hemolysis in G6PD deficiency), 
prior infection (defined by clinical presentation or con-
firmation by laboratory investigation), and presence of 
abdominal pain at admission between the two groups. 
Factors associated with significantly higher hemolysis 
compared to mild included younger age, male gender, 
higher alkaline phosphatase enzyme level, presence of 
fever at admission, presence of vomiting during the at-
tack, and a negative family history for G6PD deficiency 
(Table 1).
DISCUSSION
G6PD deficiency is still the most common of all clini-
cally significant enzyme defects, not only in hematology, 
but in human biology as a whole. A variety of drugs, 
foods and infections cause hemolytic anemia in per-
sons with the deficiency, and nonhematologic sequelae 
have been claimed as well.6-9 Using classical biochemical 
techniques, an enormous diversity of mutations causing 
G6PD deficiency have been documented in hundreds 
of publications.8-11
This is the first report on predisposing factors for 
severe hemolysis in G6PD deficiency. Our results re-
vealed that the frequency of the enzyme deficiency in 
males (76%) was higher than in females (24%). A high-
er incidence in males than females was also reported in 
many studies.12,13 The incidence of the severe form of 
the enzyme deficiency in females is considerably lower, 
with most of the cases being of the mild form of the 
enzyme deficiency.12,13 Because G6PD deficiency is a 
sex-linked disorder, it shows full expression in hetero-
zygous males and homozygous females. Heterozygous 
females exhibit variations in expression depending on 
the degree of inactivation. Thus, heterozygous females 
may have undetectable, intermediate, and normal en-
zyme levels in their erythrocytes. Our results showed 
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that male gender is a predisposing factor for severe he-
molysis, which probably reflects the fact that those fe-
males with so-called mild deficiency were heterozygous 
for the deficient gene. 
This is the first report to show an association be-
tween age at presentation and severity of hemolysis. 
Younger patients are probably exposed to more than 
one incriminating factor. Infection-induced hemolysis 
is a common cause of clinically significant hemolysis. 
Many different types of infections may cause signifi-
cant hemolysis in the G6PD deficient patient.14-19 The 
mechanism by which this occurs is not clear, but it has 
been suggested that leukocytes damage erythrocytes in 
their environment by discharging active oxygen species 
during phagocytosis, or perhaps nitric oxide might also 
play such a role.14,20 Our results revealed fever as a sig-
nificant predictor of severe hemolysis. Moreover, Mean 
WBC count was higher in the severe cases, but the dif-
ference was not statistically significant.
Gastric upset, abdominal pain, and back pain are as-
sociated with severe hemolysis due to nitric oxide deple-
tion or hemoglobin urea. Our results showed vomiting 
as a significant predictor of severe hemolysis, but no 
difference in the frequency of abdominal pain between 
the two groups. Our data showed that a negative fam-
ily history for hemolysis secondary to G6PD deficiency 
is a significant predictor factor for severe hemolysis 
probably due to attitude and knowledge of their fami-
lies. Patients with a positive family history for hemo-
lysis secondary to G6PD deficiency probably institute 
preventive measures for exposure to oxidant stresses 
or they seek medical care earlier following exposure to 
oxidant stresses. 
A limitation of the study is that it was retrospec-
tive and another problem is that males and females 
were pooled. No biochemical test can accurately iden-
tify all female heterozygotes. Heterozygosity may have 
resulted in a more mild form of hemolysis, but this is 
not accounted for in the study. Many studies of G6PD 
deficiency have, for this reason, included males only. 
Increased hemolysis is not always a major factor in the 
development of neonatal jaundice.21 Moreover, even in 
the absence of all known triggers, jaundice can occur. 
An alternative factor influencing the development of 
jaundice may be defective liver enzymes.22-25 Our data 
showed that liver enzymes were affected more in the 
severe cases. Severe cases had a higher alkaline phos-
phatase enzyme level than mild cases. Although mean 
ALT was higher in the severe cases the difference was 
not statistically significant.
In summary, this is the first study to demonstrate 
factors that predict severe hemolysis in patients with 
G6PD deficiency. We identified some factors that 
predict severe hemolysis among G6PD deficient 
individuals. Cord blood screening of G6PD level is 
indicated in a high-risk population. Once G6PD-
deficiency is confirmed, close monitoring, health 
Table 1. Baseline characteristics and results of the analysis among the two study 
groups.
Number
Cases with mild 
hemolysis
Cases with severe 
hemolysis
n=349 n=79
age (years)a 
   Mean, standard deviation 4.2 (2.9) 2.9 (1.9)
   Range 0.2-13 1-13
Sex (n, %)a
   Male 255 (73) 71 (90)
   Female 94 (27) 8 (10)
alkaline phosphatase enzyme level 
(U/L) (mean, standard deviation)a 169 (18) 252 (25)
Presence of feverb 48% 73%
Presence of vomitingc 20% 34%
Negative family history of G6PD 
deficiencyd 37% 55%
Presence of abdominal pain 16.3% 16.5%
ingestion or exposure to favabeans
   Fresh 45% 31%
   Cooked 42% 52%
   Dried 13% 17%
ingestion of drugs 4% 2%
Rh
   Positive 92.4% 92.8%
   Negative 6.6% 6.8%
Blood group
   O 36.5% 36.5%
   a 42.1% 32.4%
   B 16.1% 21.6%
   aB 5.3% 9.5%
History of neonatal jaundice 41% 31%
Mean wBCs ×109 14.1 19.3
Mean aLT enzyme level(U/L) 47 28
Mean aST enzyme level(U/L) 38 37
aP<.05, bP<.01, cP=.006 dP=.005 severe vs. mild hemolysis groups. wBC: white blood cell; aLT: alanine 
aminotransferase; aST: aspartate aminotransferase.               
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education regarding triggers, and proper follow-up 
for hemolysis can prevent severe hemolysis, thus de-
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